Topotecan transscleral chemoplaque for retinoblastoma
Topotecan in treatment of retinoblastoma
Sponsor: 3TOphthalmics
Enrolling: Male and Female Patients
Study Length: 100 Days
Clinic Visits: 5
IRB Number: AAAU1956
Contact: Marzhan Atakulova: 212-305-0011 / ma3448@cumc.columbia.edu
Additional Study Information: In this research study we want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. This study will investigate the utility of a chemoplaque(s) to salvage eyes involved with retinoblastoma. Chemoplaque is a device that is implanted on the surface of the eye and it releases chemotherapy over a period of time. The goal of the study is to further determine/assess the safety and efficacy and optimal chemotherapy dosage for retinoblastoma. The chemoplaque will be placed following the first exam under anesthesia and this involves a surgery wherein the disc that will release the chemotherapy medication would be placed under the conjunctiva (surface lining of the eye) and will be glued with tissue glue to the sclera (coating of the eye).The chemoplaque will remain in the eye till day 42 when the chemoplaque will be removed.Eye exam under anesthesia will be performed on Day 0, Day 21, Day 42 and Day 42 (prior to chemoplaque removal).Blood will be drawn periodically for testing the blood parameters (CBC) and to evaluate toxicity of the medication.Study subjects will be followed till Day 84 when the trial will be completed.
This study is closed
Investigator
Brian Marr, MD
Do You Qualify?
Children under 8 years Yes No
Diagnosed with retinoblastoma Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Marzhan Atakulova
ma3448@cumc.columbia.edu
212-305-0011